What We Should Know:
- Glooko Inc., a provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly’s connected insulin pen solutions.
- The technology collaboration will ease insulin management for people with diabetes and their healthcare providers in markets outside the U.S., via integration of Lilly’s Tempo Pen™ and
Read More
smart insulin pen cap
Abbott and Sanofi Partner to Integrate Glucose Sensing and Insulin Data
- Abbott (ABT) and Sanofi partner to integrate to developing tools that combine the FreeStyle Libre technology with Sanofi′s insulin dosing information for future smartpens, insulin titration apps and cloud software. - The integration will enable both people with diabetes and their doctors to make better-informed treatment decisions around medication, nutrition, and lifestyle.Abbott (ABT) and Sanofi, today announced they are partnering to integrate glucose sensing and insulin delivery
Read More
Glooko Integrates Insulin Data with Companion Medical’s Smart Insulin Injection Pen
Glooko and Companion Medical have announced an integrated data partnership agreement that will enable insulin data from users of the InPen Smart Insulin Injection Pen to be integrated into the Glooko Enterprise diabetes data management system and Glooko Mobile App.
Impact of Integration
The announcement of this integration is significant because InPen is the first “smart” insulin pen to introduce its data integration and compatibility with the Glooko platform
Read More
Abbott Integrates Insulin Dose Data with Novo Nordisk Insulin Pens
Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The integration between Abbott and Novo Nordisk’s products will enable healthcare professionals, caregivers and people with diabetes to view glucose and insulin data together to help
Read More
Glooko Launches Integration with Novo Nordisk Insulin Pen
Today, Glooko announced the launch of their integration with the Novo Nordisk connected insulin pen on our diasend® platform and the release of their Annual Diabetes Report. With diasend, doctors were able to see and advise patients based on recorded insulin dose data from connected Novo Nordisk pens without having to invest additional time. Now, to raise the bar for patient convenience even further, Glooko is launching the ability to also upload pen data remotely – straight from any near field
Read More
Roche Integrates Insulin Data from Novo Nordisk with Diabetes Management Solutions
Roche has signed a development and collaboration agreement with Novo Nordisk, a leader in innovating the therapy of diabetes and obesity. Under the terms of the development and collaboration agreement, the partners will integrate insulin data from Novo Nordisk's connected pen to Roche's open ecosystem, synchronizing with its suite of digital diabetes management solutions including mySugr.People with diabetes spend an average of one hour per day on self-care and have to make up to 50 therapy
Read More
Common Sensing Raises $6.6M to Scale Smart Insulin Pen Cap
Common Sensing, an evidence-based, data-driven injectable-medicine startup has raised $6.6 million in Series A funding led by Waterline Ventures. New World Health and Royal Philips with participation from Haselmeier. The Cambridge, MA-based digital health startup plans to use the funds to accelerate Common Sensing's manufacturing and commercial operations for its smart insulin pen cap solution, Gocap. The IP-protected dose monitoring solution enables patients and providers to better utilize
Read More
